![]() |
![]() |
![]() |
|
![]() |
2015 Publication |
![]() |
|
Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.
World J Clin Oncol. 2015 Dec 10;6(6):184-8. doi: 10.5306/wjco.v6.i6.184.
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
Clin Cancer Res. 2015 Jun 5. pii: clincanres.0335.2015. [Epub ahead of print].
Bisphosphonates as new anticancer agents?
Bull Cancer. 2015 Apr;102(4):297-9.
The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways.
PLoS One. 2015 Apr 17;10(4):e0124487.
Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.
DNA Repair. 2015 Feb 11. pii: S1568-7864(15)00023-3.
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.
Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12.
|
This web site is a development of the Genomics and Pharmacology Facility, Developmental Therapeutics Branch (DTB), Center for Cancer Research (CCR), National Cancer Institute (NCI). |
If you have questions or comments about this site, please send them to: webadmin@discover.nci.nih.gov. Please see our credits page and disclaimer for more information. |